Analysis of seven SARS-CoV-2 rapid antigen tests in detecting omicron (B.1.1.529) versus delta (B.1.617.2) using cell culture supernatants and clinical specimens
Purpose Omicron is rapidly spreading as a new SARS-CoV-2 variant of concern (VOC). The question whether this new variant has an impact on SARS-CoV-2 rapid antigen test (RAT) performance is of utmost importance. To obtain an initial estimate regarding differences of RATs in detecting omicron and delta, seven commonly used SARS-CoV-2 RATs from different manufacturers were analysed using cell culture supernatants and clinical specimens. Methods For this purpose, cell culture-expanded omicron and delta preparations were serially diluted in Dulbecco’s modified Eagle’s Medium (DMEM) and the Limit of Detection (LoD) for both VOCs was determined. Additionally, clinical specimens stored in viral transport media or saline (n = 51) were investigated to complement in vitro results with cell culture supernatants. Ct values and RNA concentrations were determined via quantitative reverse transcription polymerase chain reaction (RT-qPCR). Results The in vitro determination of the LoD showed no obvious differences in detection of omicron and delta for the RATs examined. The LoD in this study was at a dilution level of 1:1,000 (corresponding to 3.0—5.6 × $ 10^{6} $ RNA copies/mL) for tests I–V and at a dilution level of 1:100 (corresponding to 3.7—4.9 × $ 10^{7} $ RNA copies/mL) for tests VI and VII. Based on clinical specimens, no obvious differences were observed between RAT positivity rates when comparing omicron to delta in this study setting. Overall positivity rates varied between manufacturers with 30–81% for omicron and 42–71% for delta. Test VII was only conducted in vitro with cell culture supernatants for feasibility reasons. In the range of Ct < 23, positivity rates were 50–100% for omicron and 67–93% for delta. Conclusion In this study, RATs from various manufacturers were investigated, which displayed no obvious differences in terms of analytical LoD in vitro and RAT positivity rates based on clinical samples comparing the VOCs omicron and delta. However, differences between tests produced by various manufacturers were detected. In terms of clinical samples, a focus of this study was on specimens with high virus concentrations. Further systematic, clinical and laboratory studies utilizing large datasets are urgently needed to confirm reliable performance in terms of sensitivity and specificity for all individual RATs and SARS-CoV-2 variants..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Infection - 51(2022), 1 vom: 20. Mai, Seite 239-245 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jungnick, Sabrina [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Comparison |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s15010-022-01844-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR049156985 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049156985 | ||
| 003 | DE-627 | ||
| 005 | 20230519161124.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230127s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-022-01844-5 |2 doi | |
| 035 | |a (DE-627)SPR049156985 | ||
| 035 | |a (SPR)s15010-022-01844-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jungnick, Sabrina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of seven SARS-CoV-2 rapid antigen tests in detecting omicron (B.1.1.529) versus delta (B.1.617.2) using cell culture supernatants and clinical specimens |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Purpose Omicron is rapidly spreading as a new SARS-CoV-2 variant of concern (VOC). The question whether this new variant has an impact on SARS-CoV-2 rapid antigen test (RAT) performance is of utmost importance. To obtain an initial estimate regarding differences of RATs in detecting omicron and delta, seven commonly used SARS-CoV-2 RATs from different manufacturers were analysed using cell culture supernatants and clinical specimens. Methods For this purpose, cell culture-expanded omicron and delta preparations were serially diluted in Dulbecco’s modified Eagle’s Medium (DMEM) and the Limit of Detection (LoD) for both VOCs was determined. Additionally, clinical specimens stored in viral transport media or saline (n = 51) were investigated to complement in vitro results with cell culture supernatants. Ct values and RNA concentrations were determined via quantitative reverse transcription polymerase chain reaction (RT-qPCR). Results The in vitro determination of the LoD showed no obvious differences in detection of omicron and delta for the RATs examined. The LoD in this study was at a dilution level of 1:1,000 (corresponding to 3.0—5.6 × $ 10^{6} $ RNA copies/mL) for tests I–V and at a dilution level of 1:100 (corresponding to 3.7—4.9 × $ 10^{7} $ RNA copies/mL) for tests VI and VII. Based on clinical specimens, no obvious differences were observed between RAT positivity rates when comparing omicron to delta in this study setting. Overall positivity rates varied between manufacturers with 30–81% for omicron and 42–71% for delta. Test VII was only conducted in vitro with cell culture supernatants for feasibility reasons. In the range of Ct < 23, positivity rates were 50–100% for omicron and 67–93% for delta. Conclusion In this study, RATs from various manufacturers were investigated, which displayed no obvious differences in terms of analytical LoD in vitro and RAT positivity rates based on clinical samples comparing the VOCs omicron and delta. However, differences between tests produced by various manufacturers were detected. In terms of clinical samples, a focus of this study was on specimens with high virus concentrations. Further systematic, clinical and laboratory studies utilizing large datasets are urgently needed to confirm reliable performance in terms of sensitivity and specificity for all individual RATs and SARS-CoV-2 variants. | ||
| 650 | 4 | |a SARS-CoV-2 rapid antigen test |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Comparison |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Omicron (B.1.1.529) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Delta (B.1.617.2) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Variants of concern |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Hobmaier, Bernhard |4 aut | |
| 700 | 1 | |a Paravinja, Natali |4 aut | |
| 700 | 1 | |a Mautner, Lena |4 aut | |
| 700 | 1 | |a Hoyos, Mona |4 aut | |
| 700 | 1 | |a Konrad, Regina |4 aut | |
| 700 | 1 | |a Haase, Maren |4 aut | |
| 700 | 1 | |a Baiker, Armin |4 aut | |
| 700 | 1 | |a Eberle, Ute |4 aut | |
| 700 | 1 | |a Bichler, Magdalena |4 aut | |
| 700 | 1 | |a Treis, Bianca |4 aut | |
| 700 | 1 | |a Okeyo, Mercy |4 aut | |
| 700 | 1 | |a Streibl, Barbara |4 aut | |
| 700 | 1 | |a Wimmer, Clara |4 aut | |
| 700 | 1 | |a Hepner, Sabrina |4 aut | |
| 700 | 1 | |a Sprenger, Annika |4 aut | |
| 700 | 1 | |a Berger, Carola |4 aut | |
| 700 | 1 | |a Weise, Laura |4 aut | |
| 700 | 1 | |a Dangel, Alexandra |4 aut | |
| 700 | 1 | |a Ippisch, Siegfried |4 aut | |
| 700 | 1 | |a Jonas, Walter |4 aut | |
| 700 | 1 | |a Wildner, Manfred |4 aut | |
| 700 | 1 | |a Liebl, Bernhard |4 aut | |
| 700 | 1 | |a Ackermann, Nikolaus |4 aut | |
| 700 | 1 | |a Sing, Andreas |4 aut | |
| 700 | 1 | |a Fingerle, Volker |0 (orcid)0000-0002-3835-5646 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d München : Urban & Vogel, 1973 |g 51(2022), 1 vom: 20. Mai, Seite 239-245 |w (DE-627)SPR032536909 |w (DE-600)2006315-5 |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2022 |g number:1 |g day:20 |g month:05 |g pages:239-245 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s15010-022-01844-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2022 |e 1 |b 20 |c 05 |h 239-245 | ||